within Pharmacolibrary.Drugs.ATC.L;

model L01EA04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 0.00106,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.223,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007333333333333333,
    Tlag           = 60,            
    Vdp             = 0.297,
    k12             = 86.5,
    k21             = 86.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bosutinib is an oral tyrosine kinase inhibitor used primarily for the treatment of chronic myelogenous leukemia (CML) in adults. It is approved and utilized as a targeted therapy in patients who are resistant or intolerant to prior therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult patients with chronic phase chronic myelogenous leukemia after oral administration of bosutinib.</p><h4>References</h4><ol><li><p>Abbas, R, &amp; Hsyu, PH (2016). Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. <i>Clinical pharmacokinetics</i> 55(10) 1191–1204. DOI:<a href=&quot;https://doi.org/10.1007/s40262-016-0391-6&quot;>10.1007/s40262-016-0391-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27113346/&quot;>https://pubmed.ncbi.nlm.nih.gov/27113346</a></p></li><li><p>Abbas, R, et al., &amp; Sonnichsen, D (2011). Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. <i>Journal of clinical pharmacology</i> 51(12) 1721–1727. DOI:<a href=&quot;https://doi.org/10.1177/0091270010387427&quot;>10.1177/0091270010387427</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21148045/&quot;>https://pubmed.ncbi.nlm.nih.gov/21148045</a></p></li><li><p>Abbas, R, et al., &amp; Sonnichsen, D (2015). Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. <i>Drug metabolism and personalized therapy</i> 30(1) 57–63. DOI:<a href=&quot;https://doi.org/10.1515/dmdi-2014-0026&quot;>10.1515/dmdi-2014-0026</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25803093/&quot;>https://pubmed.ncbi.nlm.nih.gov/25803093</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EA04;
